The purpose of this study is to find out whether a biopsy technique called transbronchial cryobiopsy (TBCB) is a safe alternative to the standard biopsy procedure (transbronchial forceps biopsy; TBFB). The study researchers think that TBCB may provide better biopsy samples to help diagnose lung disease.

Inclusion Criteria:

• 18 years of age or greater
• Patients with known or suspected diagnosis of cancer and indeterminant pulmonary nodules or diffuse parenchymal lung disease with non-diagnostic clinical profiles for whom a lung biopsy is deemed useful for diagnosis.

Exclusion Criteria:

• Patients with pulse oximetry less than 92% on oxygen delivery up to 2 L nasal cannula.

• Uncorrectable coagulopathy defined as:

  • Platelet count <50,000 x 10^9/L or
  • prothrombin time international normalized ratio >1.5

• Known pulmonary hypertension or echocardiographic pulmonary artery systolic pressure >50mmHg

• A secure diagnosis based on clinical and high-resolution CT scan data.

• Antiplatelet therapy that cannot be held for more than 5 days.

• Any patient deemed unfit to undergo bronchoscopy by the proceduralist

• Female patients with a positive pregnancy test within 30 days of the planned study procedure

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.